Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis - PubMed (original) (raw)

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis

R O Williams et al. Proc Natl Acad Sci U S A. 1994.

Abstract

Anti-CD4 treatment is reported to prevent collagen-induced arthritis if administered before the onset of clinical disease but has relatively little effect on established arthritis. In contrast, we have recently shown that anti-tumor necrosis factor alpha/beta (TNF) treatment reduces the severity of established arthritis. We now study the effect of combined administration of anti-CD4 monoclonal antibody (YTS 191.1.2/YTA 3.1.2) and anti-TNF monoclonal antibody (TN3-19.12) in established arthritis. Anti-CD4 treatment caused some reduction in paw-swelling but did not significantly prevent joint erosion. A suboptimal dose of anti-TNF alone had no significant effect on arthritis. In contrast, anti-CD4 plus suboptimal anti-TNF significantly reduced paw-swelling, limb involvement, and joint erosion. As previously reported, an optimal dose of anti-TNF alone inhibited paw-swelling, limb involvement, and joint erosion. However, optimal anti-TNF combined with anti-CD4 caused significantly greater reductions in paw-swelling and joint erosion than those achieved by optimal anti-TNF alone. Coadministration of anti-CD4 was also effective in preventing an antibody response to the hamster anti-TNF antibody, which may have implications for long-term therapy in human disease. Thus anti-CD4 acts synergistically with anti-TNF in ameliorating established collagen-induced arthritis and this combined therapeutic approach may provide effective long-term control of rheumatoid arthritis.

PubMed Disclaimer

Cited by

An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab.
Sidiropoulos PI, Siakka P, Raptopoulou A, Mamoulaki M, Choulaki C, Koutala H, Kouroumali H, Kritikos H, Boumpas DT. Sidiropoulos PI, et al. Ann Rheum Dis. 2006 Apr;65(4):538-41. doi: 10.1136/ard.2005.036152. Epub 2005 Aug 26. Ann Rheum Dis. 2006. PMID: 16126800 Free PMC article. Clinical Trial.
Low CD4/CD8 T-cell ratio associated with inflammatory arthropathy in human T-cell leukemia virus type I Tax transgenic mice.
Ohsugi T, Kumasaka T. Ohsugi T, et al. PLoS One. 2011 Apr 1;6(4):e18518. doi: 10.1371/journal.pone.0018518. PLoS One. 2011. PMID: 21483764 Free PMC article.
Biological insights from clinical trials with anti-TNF therapy.
Feldmann M, Charles P, Taylor P, Maini RN. Feldmann M, et al. Springer Semin Immunopathol. 1998;20(1-2):211-28. doi: 10.1007/BF00832008. Springer Semin Immunopathol. 1998. PMID: 9836378 No abstract available.
Etanercept: a review of its use in rheumatoid arthritis.
Jarvis B, Faulds D. Jarvis B, et al. Drugs. 1999 Jun;57(6):945-66. doi: 10.2165/00003495-199957060-00014. Drugs. 1999. PMID: 10400407 Review.
Future prospects for anti-cytokine treatment.
Feldmann M, Miotla J, Paleolog E, Williams R, Malfait AM, Taylor P, Brennan FM, Maini RN. Feldmann M, et al. Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i119-22. doi: 10.1136/ard.59.suppl_1.i119. Ann Rheum Dis. 2000. PMID: 11053102 Free PMC article. Review.

References

1. Biochemistry. 1972 Dec 19;11(26):4903-9 - PubMed
1. Nature. 1979 Jan 11;277(5692):131-3 - PubMed
1. Nature. 1984 Dec 6-12;312(5994):548-51 - PubMed
1. J Immunol. 1988 Aug 1;141(3):834-41 - PubMed
1. J Immunol. 1989 Jun 1;142(11):3884-93 - PubMed

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis - PubMed (original) (raw)